Lorcaserin hydrochloride is under clinical development by Eisai and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lorcaserin hydrochloride’s likelihood of approval (LoA) and phase transition for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) took place on 02 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lorcaserin hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lorcaserin hydrochloride overview

Lorcaserin hydrochloride (Belviq, Venespri, APD356) is an antiobesity agent. It is formulated as film coated tablets and tablets for oral administration. Lorcaserin hydrochloride is indicated for treatment of chronic weight management only in conjunction with a reduced-calorie diet and increased physical activity.

Lorcaserin hydrochloride is under development for the treatment of dravet syndrome in US. It is administered through oral route in the form of tablet and suspension.

Lorcaserin hydrochloride was under development for the treatment of obesity in Japan. It was also under development for smoking cessation and Obesity in Canada.

Eisai overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Quick View Lorcaserin hydrochloride LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Lorcaserin hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
Key Developers
  • Sponsor Company: Eisai
  • Originator: Arena Pharmaceuticals
Highest Development Stage
  • Marketed

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.